Clinical Trial Update: An Open-Label Study of DCCR Tablet in Patients With PWS [Phase 3]

View source ↗

Summary

An open-label Phase 3 study of DCCR Tablet in Prader-Willi Syndrome was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• DCCR Tablet (null)

Snippet

Sponsor: Soleno Therapeutics, Inc. | Conditions: Prader-Willi Syndrome | Phase 3 | Status: WITHDRAWN